From MarketBeat:



Stock analysts at StockNews.com upgraded United Therapeutics (NASDAQ:UTHR) from a “buy” rating to a “strong-buy” rating. Other analysts also issued reports about the stock, with JPMorgan Chase & Co. raising their price target on shares of United Therapeutics. The company’s stock has a consensus rating of “Buy” and a consensus target price of $297.88. United Therapeutics had a strong 2019, with strong earnings results and insider buying and selling. Hedge funds and other institutional investors have also increased their stake in the company. Overall, the future looks bright for United Therapeutics, as it continues to develop and commercialize products for patients with chronic and life-threatening diseases.



Original: United Therapeutics (NASDAQ:UTHR) Rating Increased to Strong-Buy at StockNews.com